The discovery of broadly neutralizing antibodies (bnAbs)1 to the human immunodeficiency virus type 1 (HIV-1) in individuals during natural infection has revolutionized the search for an effective vaccine.1, 2, 3 These bnAbs function by targeting highly conserved sites on the envelope glycoprotein (Env, gp160), which is the only HIV-1 antigen on the virus surface recognized by the humoral arm of the immune system. This evidence concerns the gene ERVW-1 and infection.